Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02094898 · ClinicalTrials.gov registry record · Phase 2

Ketamine for Depression and Suicide Risk

A Phase 2 study of Depression and Suicide, sponsored by Mayo Clinic.

Completed
Registry status
Phase 2
Development phase
12
Enrollment target
1
Study location

NCT02094898: Completed Phase 2 study of Depression and Suicide, sponsored by Mayo Clinic.

NCT02094898 is a Phase 2 study of Depression and Suicide that has completed, run by Mayo Clinic. The registered enrollment target is 12 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02094898, a Phase 2 study of Depression and Suicide, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 2
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study was to find out if the medication known as ketamine could help the symptoms of depression. This drug is approved by the U.S. Food and Drug Administration (FDA) as an anesthetic agent; however, it is not approved for use in depression treatment. The FDA allowed the use of this drug in this research study.

Primary Outcome

The Montgomery Asberg Depression Scale (MADRS) is a 10-item observer rating scale assessing symptoms of depression. The score ranges from 0 (no depression) to 60 (very depressed). For this study a score of less than or equal to 9 was considered clinical remission of depression.

Conditions Studied

Interventions

  • DRUG Ketamine

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2014-09
Est. Completion 2016-08
Phase Phase 2
Mayo Clinic

2,844 total trials

What the finished NCT02094898 record still lists

NCT02094898 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Ketamine is the first listed.

NCT02094898 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT02094898 about?

NCT02094898 is a clinical study titled "Ketamine for Depression and Suicide Risk". The purpose of this research study was to find out if the medication known as ketamine could help the symptoms of depression. This drug is approved by the U.S. Food and Drug Administration (FDA) as an anesthetic agent; however, it is not approved for use in depression treatment. The FDA allowed the ...

What is the current status of trial NCT02094898?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2014-09. Estimated completion is 2016-08.

What conditions does trial NCT02094898 study?

This clinical trial studies the following conditions: Depression, Suicide.

What interventions are being tested in trial NCT02094898?

The interventions under investigation include: Ketamine (DRUG).

Who is sponsoring clinical trial NCT02094898?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02094898 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02094898's enrollment target sits among peer trials

12 654th of 679 higher than 22 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02094898, the US trial registry maintained by the National Library of Medicine. NCT02094898 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.